Back to top
more

Merck & Co. (MRK)

(Real Time Quote from BATS)

$79.98 USD

79.98
5,599,396

-0.71 (-0.88%)

Updated Aug 11, 2025 03:55 PM ET

After-Market: $80.10 +0.12 (0.15%) 4:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (68 out of 244)

Industry: Large Cap Pharmaceuticals

Zacks News

Zacks Equity Research

Roche's Tecentriq With Chemotherapy Meets Goal for TNBC

Roche's (RHHBY) phase III study evaluating the efficacy and safety of Tecentriq in combination with chemotherapy meets goal in early TNBC patients.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Merck, CVS Health, Morgan Stanley, Applied Materials and Enterprise Products Partners

The Zacks Analyst Blog Highlights: Merck, CVS Health, Morgan Stanley, Applied Materials and Enterprise Products Partners

Zacks Equity Research

Merck (MRK) Dips More Than Broader Markets: What You Should Know

Merck (MRK) closed at $76.29 in the latest trading session, marking a -0.88% move from the prior day.

Zacks Equity Research

Merck's Steglatro Non-Inferior in Cardiovascular Outcomes Study

Merck's (MRK) type 2 diabetes drug, Steglatro, achieves primary endpoint of non-inferiority in major adverse CV events compared to placebo in a late-stage cardiovascular outcomes study.

Sheraz Mian headshot

Top Stock Reports for Merck, CVS & Morgan Stanley

Today's Research Daily features new research reports on 16 major stocks, including Merck (MRK), CVS Health (CVS) and Morgan Stanley (MS).

Zacks Equity Research

Bayer Initiates a Phase III Study in Heart Failure Patients

Bayer (BAYRY) initiates a phase III study to evaluate finerenone compared to placebo in more than 5,500 symptomatic heart failure patients with a left ventricular ejection fraction.

Kinjel Shah headshot

Pharma Stock Roundup: Coronavirus Updates From ABBV, LLY, JNJ, FDA Approvals

J&J (JNJ), AbbVie (ABBV) and Lilly (LLY) make progress in coronavirus research efforts.

Zacks Equity Research

Novo Nordisk to Acquire Corvidia Therapeutics for $725M Cash

Novo Nordisk (NVO) enters into a deal to acquire Corvidia Therapeutics for an upfront payment of $725 million in cash.

Zacks Equity Research

Bristol-Myers Gets FDA Nod for Label Expansion of Opdivo

Bristol-Myers (BMY) gets FDA nod for Opdivo for the treatment of esophageal squamous cell carcinoma.

Zacks Equity Research

Clovis Completes Enrollment in Late-Stage Ovarian Cancer Study

Clovis (CLVS) is developing Rubraca as monotherapy as well as in combination with Bristol-Myers' Opdivo as first-line maintenance treatment for ovarian cancer in the phase III ATHENA study.

Zacks Equity Research

Merck (MRK) Dips More Than Broader Markets: What You Should Know

Merck (MRK) closed the most recent trading day at $81.77, moving -0.6% from the previous trading session.

Zacks Equity Research

Merck's Keytruda Fails in First-Line Bladder Cancer Study

Merck's (MRK) phase III advanced bladder cancer study on Keytruda fails to meet dual primary endpoints of overall survival (OS) or progression-free survival (PFS).

Zacks Equity Research

Merck's Antibiotic Recarbrio Gets FDA Nod for New Indication

The FDA approves Merck's (MRK) sNDA seeking approval for its antibacterial injection Recarbrio regarding a new indication. The application was filed in February 2020.

Zacks Equity Research

Bayer (BAYRY) Submits Applications for Heart Failure Drug

Bayer (BAYRY) seeks approval of chronic heart failure drug, vericiguat, in the EU and Japan.

Zacks Equity Research

AstraZeneca to Ensure Equal Access to Coronavirus Vaccine

AstraZeneca (AZN) signs three new supply deals to ensure broad and equitable global access to its COVID-19 vaccine following its successful development.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Alibaba, UnitedHealth, Merck, PetroChina and 3M

The Zacks Analyst Blog Highlights: Alibaba, UnitedHealth, Merck, PetroChina and 3M

Kinjel Shah headshot

Trump Picks 5 Coronavirus Vaccine Candidates Per NYT Report

The candidates belong to five companies, Moderna, AstraZeneca, J&J, Merck and Pfizer.

Zacks Equity Research

AstraZeneca Inks Deal to Develop RMP Inhibitors for Cancer

AstraZeneca (AZN) signs an oncology agreement with Accent Therapeutics to develop novel therapies targeting RNA-modifying proteins for treating cancer.

Zacks Equity Research

Roche Tecentriq-Avastin Combo Gets FDA Nod for Liver Cancer

FDA approves Roche's (RHHBY) sBLA seeking approval of the Tecentriq-Avastin combo to treat HCC patients who have not received prior systemic therapy.

Sheraz Mian headshot

Top Stock Reports for Alibaba, UnitedHealth & Merck

Today's Research Daily features new research reports on 16 major stocks, including Alibaba Group (BABA), UnitedHealth (UNH) and Merck (MRK).

Zacks Equity Research

Box, Ulta Beauty, Merck, Gilead and Johnson & Johnson highlighted as Zacks Bull and Bear of the Day

Box, Ulta Beauty, Merck, Gilead and Johnson & Johnson highlighted as Zacks Bull and Bear of the Day

Benjamin Rains headshot

3 Strong Pharmaceutical and Biotech Stocks to Buy for Coronavirus Immunity

Let's dive into three large-cap pharmaceutical and biotech stocks that appear set to grow during the pandemic-induced downturn and the eventual recovery...

Sweta Killa headshot

Best-Performing ETFs of Last Week

While the rally was broad-based, airline and banking industry led the way higher last week.

Zacks Equity Research

Novartis' (NVS) Breast Cancer Drug Gets Positive CHMP Opinion

Novartis (NVS) gets positive CHMP opinion for breast cancer drug, Piqray. The company also announces other pipeline updates.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Merck, Glaxo, Roche, Sanofi and Bristol-Myers

The Zacks Analyst Blog Highlights: Merck, Glaxo, Roche, Sanofi and Bristol-Myers